- Home
- CATX
as 12-17-2024 4:00pm EST
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 782.7M | IPO Year: | N/A |
| Target Price: | $17.25 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.50 - $19.10 | Next Earning Date: | 11-12-2024 |
| Revenue: | $1,557,000 | Revenue Growth: | -73.52% |
| Revenue Growth (this year): | -15.83% | Revenue Growth (next year): | -42.57% |
Stock Insider Trading Activity of Perspective Therapeutics Inc. (CATX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HENSON HEIDI | CATX | Director | Dec 4 '24 | Buy | $3.85 | 25,975 | $100,003.75 | 25,975 | |
| Spoor Johan M. | CATX | CEO | Dec 4 '24 | Buy | $3.77 | 8,000 | $30,132.00 | 36,257 | |
| Williamson Robert F III | CATX | Director | Nov 25 '24 | Buy | $3.64 | 6,266 | $22,813.51 | 427,439 | |
| Hunt Jonathan Robert | CATX | Chief Financial Officer | Nov 25 '24 | Buy | $3.74 | 12,829 | $48,974.26 | 48,800 | |
| Spoor Johan M. | CATX | CEO | Nov 25 '24 | Buy | $3.79 | 26,500 | $100,468.00 | 36,257 |
Latest Perspective Therapeutics Inc. News
CATX Breaking Stock News: Dive into CATX Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 days ago
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
MT Newswires
22 days ago
B. Riley Securities Adjusts Price Target on Perspective Therapeutics to $9 From $17, Keeps Buy Rating
TipRanks
22 days ago
Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital
TipRanks
22 days ago
Perspective Therapeutics downgraded to Neutral from Buy at BofA
MT Newswires
23 days ago
BofA Securities Downgrades Perspective Therapeutics to Neutral From Buy, Price Target is $6
MT Newswires
23 days ago
RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk
MT Newswires
a month ago
Perspective Therapeutics Pursuing Dose Escalation Study in Neuroendocrine Tumors
![Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium](https://cdn.finquota.com/news/691c9f5f-3a36-48c6-b49e-50a5ed2d850f.jpg)
GlobeNewswire
a month ago
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
Compare CATX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CATX Perspective Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.